Science&Humans and Quikcard Partner to Launch National Hormone Health Benefit in Canada

Science&Humans and Quikcard have launched a national hormone health benefit, giving Canadian employees access to clinician-led care for hormone and metabolic conditions through their workplace benefits plans Montreal Gazette. The move, announced June 22, 2026, puts lab testing, virtual doctor visits, personalized treatment, and ongoing follow-up under a single employer-sponsored program — available to plan members across the country.
About 1 in 3 Canadian adults report symptoms tied to hormonal imbalance — including low energy, poor sleep, and brain fog — yet specialized care has historically meant months-long waits for a referral Edmonton Sun. This partnership aims to close that gap through a digital-first model backed by $10 million CAD raised in January 2026.
The Science&Humans program bundles four things into one benefit: at-home blood diagnostics, virtual consultations with licensed clinicians, a personalized treatment plan, and regular follow-up care Toronto Sun. That last piece matters most. Hormone conditions like perimenopause, andropause, and metabolic decline don't resolve with a single visit — they require ongoing monitoring and dose adjustments over time.
Quikcard currently serves more than 37,200 Canadian businesses and cardholders Sault This Week. By embedding Science&Humans directly into Quikcard's benefits platform, plan members can access care without navigating the public referral system. Chris Biddeson, Director of Business Development at Quikcard, said the partnership gives members "access to specialized care in an area that is increasingly important to our plan members."
The Quikcard deal is the latest in a fast-moving 2026 for Science&Humans. In January, the company closed a $10 million CAD Series A led by Pender Ventures, with backing from WELL Health Technologies and entrepreneur Michele Romanow Cold Lake Sun. On June 16 — just six days before this launch — S&H debuted Healthspan, Canada's first at-home blood collection kit built specifically for hormone markers.
Romanow, comparing hormone health to the mental health movement of a decade ago, said it is "moving into the mainstream... with a profound impact on people's lives and economic participation" Edmonton Examiner. CEO Aftab Pashaw framed the company's mission plainly: "We built Science&Humans to change the fragmented, reactive care model, focusing instead on root causes and long-term outcomes."
Untreated hormone conditions carry a measurable cost for employers. A 2024–2025 study estimated that menopause symptoms alone cost the Canadian economy billions in lost productivity each year Shoreline Beacon. About 75% of menopausal women experience symptoms disruptive enough to affect their daily lives. That translates directly into absenteeism and "presenteeism" — showing up to work but functioning far below capacity.
The Canadian menopause market was valued at $729.7 million in 2024 and is projected to grow steadily through 2030 The Observer. Benefits providers like Quikcard are moving early. Competitor June Health raised $2.4 million in June 2026 to expand its women's hormone platform, signaling that employer-backed hormone care is quickly becoming a standard offering rather than a niche perk.
Not everyone sees this as a win. Medical groups like the Society of Obstetricians and Gynaecologists of Canada have warned about an "online disinformation" wave around hormone therapy, urging that marketing not outpace clinical evidence Edmonton Sun. Some patient reviews also flag limited back-and-forth once treatment begins — a known tension in high-volume telehealth models.
There is also an equity concern. These benefits flow through employer plans, meaning low-income and uninsured Canadians are largely left out of the "hormone health revolution" Toronto Sun. As digital clinics scale up for plan members with robust coverage, those relying on the public system still face the same long waits that made this gap visible in the first place.
Publishers
8
Articles
8
Reach
8